Clinical trial
Post Approval Study of the Eversense® Continuous Glucose Monitoring
NCT03908125
Study timeline
Study start (actual)2019-03-19Date precision: day
Registry last updated2025-06-12
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Interventions
Eversense® CGM SystemDEVICE
Sponsors & collaborators
Senseonics, Inc.lead sponsor
Mapped research locations
HoustonTexas, United States1BaltimoreMaryland, United States1AtlantaGeorgia, United States1San AntonioTexas, United States1AustinTexas, United States1Fort LauderdaleFlorida, United States1AlbanyNew York, United States1Newport BeachCalifornia, United States1WilmingtonNorth Carolina, United States1GreenvilleNorth Carolina, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03908125 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.